Araruna Maria Elaine Cristina, Alves Júnior Edvaldo Balbino, de Lima Serafim Catarina Alves, Pessoa Matheus Marley Bezerra, de Souza Pessôa Michelle Liz, Alves Vitória Pereira, Sobral Marianna Vieira, da Silva Marcelo Sobral, Alves Adriano Francisco, de Paiva Sousa Maria Carolina, Araújo Aurigena Antunes, Batista Leônia Maria
Postgraduate Program in Natural and Synthetic Bioactive Products, Health Sciences Center, Federal University of Paraíba (UFPB), João Pessoa CEP 58051-970, PB, Brazil.
Department of Physiology and Pathology, Health Sciences Center, Federal University of Paraíba (UFPB), João Pessoa CEP 58051-970, PB, Brazil.
Pharmaceuticals (Basel). 2024 Dec 26;18(1):18. doi: 10.3390/ph18010018.
(-)-Fenchone is a bicyclic monoterpene present in the plant species Mill, L. (tuja), and (lavender). These plants have therapeutic value in the treatment of intestinal disorders.
To evaluate intestinal anti-inflammatory activity in an acute and chronic trinitrobenzene sulphonic acid (TNBS)-induced colitis model in rats.
Intestinal anti-inflammatory effects were assessed using the acute and chronic TNBS-induced colitis model in rats. The mechanisms were evaluated from colonic tissue fragments of the acute and chronic models.
Oral administration of the (-)-fenchone (37.5-300 mg/kg) acute phase or (150 mg/kg) ( < 0.001) chronic phase reduced the macroscopic lesion score, ulcerative area, intestinal weight/length ratio, and diarrheal index in TNBS-treated animals. At a dose of 150 mg/kg, the acute and chronic phase decreased malondialdehyde (MDA) and myeloperoxidase (MPO) ( < 0.001), restored glutathione (GSH) levels and superoxide dismutase (SOD) ( < 0.001), decreased immunomarking for factor nuclear kappa B (NF-κB) and levels of interleukin (IL)-1 and tumor necrosis factor α (TNF-α), and maintained IL-10 and TGF-β basal levels. Furthermore, increased immunostaining for zonula occludens 1 (ZO-1) was observed.
(-)-fenchone has intestinal anti-inflammatory activity related to cytoprotection of the intestinal barrier, as well as antioxidant and immunomodulatory effects.
（-）-小茴香酮是一种双环单萜，存在于植物物种北美香柏、 （杜松）和薰衣草中。这些植物在治疗肠道疾病方面具有治疗价值。
在大鼠急性和慢性三硝基苯磺酸（TNBS）诱导的结肠炎模型中评估肠道抗炎活性。
使用大鼠急性和慢性TNBS诱导的结肠炎模型评估肠道抗炎作用。从急性和慢性模型的结肠组织片段评估其作用机制。
口服（-）-小茴香酮（37.5 - 300 mg/kg）急性期或（150 mg/kg）（P < 0.001）慢性期可降低TNBS处理动物的宏观病变评分、溃疡面积、肠重/长度比和腹泻指数。在150 mg/kg剂量下，急性期和慢性期均可降低丙二醛（MDA）和髓过氧化物酶（MPO）（P < 0.001），恢复谷胱甘肽（GSH）水平和超氧化物歧化酶（SOD）（P < 0.001），降低核因子κB（NF-κB）的免疫标记以及白细胞介素（IL）-1和肿瘤坏死因子α（TNF-α）的水平，并维持IL-10和转化生长因子β（TGF-β）的基础水平。此外，还观察到紧密连接蛋白1（ZO-1）的免疫染色增加。
（-）-小茴香酮具有与肠道屏障细胞保护相关的肠道抗炎活性，以及抗氧化和免疫调节作用。
